

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER OF PATENTS AND TRADEMARKS Washington D.C. 20231 www.uspto.gov

DATE MAILED: 09/13/2002

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/853,257	05/10/2001	Bonnie L. Bassler	PUNIV.002A	5035
20995	7590 09/13/2002			
KNOBBE MARTENS OLSON & BEAR LLP			EXAMINER	
2040 MAIN STREET FOURTEENTH FLOOR			DUFFY, PAT	RICIA ANN
IRVINE, CA	91614		ART UNIT	PAPER NUMBER
			1645	10

Please find below and/or attached an Office communication concerning this application or proceeding.



## UNITED SEES DEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

091853,257

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXAMINER				
ART UNIT	PAPER NUMBER			
	8-			

DATE MAILED:

## Please find below a communication from the EXAMINER in charge of this application

1. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

In particular the sequences in Figure 1 are not listed in the sequence listing and are not identified by sequence identifier in the Brief Description of the Drawings.

Applicant is given ONE MONTH from the mailing date of this communication within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

3. Any inquiry of a general nature or relating to the status of this general application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Papers relating to this application may be submitted to Technology Center 1600, Group 1640 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Should applicant wish to FAX a response, the current FAX number for Group 1600 is (703) 308-4242.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patricia A. Duffy, Ph.D. whose telephone number is (703) 305-7555. The examiner can normally be reached on Monday-Friday from 6:30 AM to 3:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith, can be reached at (703) 308-3995.

Patricia A. Duffy, Ph.D. Primary Examiner, Group 1600 September 11, 2002

Patricia A. Duffy, Ph.D. Primary Examiner Group 1600

Application No.: 09/853,257

## NOTICE TO COMPLY WITTEREQUIREMENTS FOR PATENT AND LICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

<i>Ч</i> Ч а	This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's applicant is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 DG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. T	his application does not contain, as a separate part of the disclosure on paper copy, a "Sequence isting" as required by 37 C.F.R. 1.821(c).
3. A	copy of the "Sequence Listing" in computer readable form has not been submitted as required by 7 C.F.R. 1.821(e).
С с	copy of the "Sequence Listing" in computer readable form has been submitted. However, the ontent of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 nd/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
ഥ aı	he computer readable form that has been filed with this application has been found to be damaged nd/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute applied by 37 C.F.R. 1.825(d).
6. TI	he paper copy of the "Sequence Listing" is not the same as the computer readable from of the Sequence Listing" as required by 37 C.F.R. 1.821(e).
7.0	ther: <u>Sequences</u> in Figures not in Sequence Listing
Applica	ant Must Provide:
M An ∰	substitute computer readable form (CRF) copy of the "Sequence Listing".
An ir into	nitial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry the specification.
🕰 appli	atement that the content of the paper and computer readable copies are the same and, where icable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 5(b) or 1.825(d).
For que	stions regarding compliance to these requirements, please contact:
For CRI PatentIr	es Interpretation, call (703) 308-4216 F Submission Help, call (703) 308-4212 n Software Program Support
Tec To	Chnical Assistance703-287-0200 Purchase PatentIn Software703-306-2600
	PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY